NCT04512872View on ClinicalTrials.gov

A Phase I Study to Evaluate the Safety and Pharmacokinetics of CT-P41 and EU-approved Prolia in Healthy Male Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

October 20, 2020

Primary Completion Date

May 4, 2021

Study Completion Date

May 4, 2021

Conditions
Healthy Male Subjects
Interventions
BIOLOGICAL

CT-P41

60 mg/mL single dose, Solution for injection in PFS

BIOLOGICAL

EU-approved Prolia

60 mg/mL single dose, Solution for injection in PFS

Trial Locations (1)

4006

Q-Pharm Pty Ltd, Herston

Sponsors

Lead Sponsor

Celltrion
All Listed Sponsors
lead

Celltrion

INDUSTRY

NCT04512872 - A Phase I Study to Evaluate the Safety and Pharmacokinetics of CT-P41 and EU-approved Prolia in Healthy Male Subjects | Biotech Hunter | Biotech Hunter